RxDoctor Payments DataLook up a doctor →

Christian Kim, MD

Endocrinology, Diabetes & Metabolism · Fort Lee, NJNPI 1457580177

Payments from drug & device makers

$20,289in general payments, 2019–2025

Across 1,444 payments — averaging $14.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • Mannkind Corporation$2K
  • Corcept Therapeutics$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • Sanofi-aventis U.S. LLC$2K
  • plus $8K from 41 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)102$2,285
Mannkind Corporation369$2,213
Corcept Therapeutics153$2,150
Novo Nordisk193$2,083
Lilly USA, LLC208$1,944
Sanofi-aventis U.S. LLC71$1,592
AstraZeneca(2 entities)29$999
Bayer48$941
Boehringer Ingelheim33$916
Amneal Pharmaceuticals LLC53$735
Medtronic(2 entities)14$488
Abbott9$429
Xeris Pharmaceuticals, Inc.33$376
Ascensia Diabetes Care US Inc.11$364
Intuity Medical Inc8$335
Radius Health, Inc.7$217
Merck15$210
Ascendis Pharma Endocrinology Inc6$200
Amarin Pharma, Inc.15$186
AbbVie(2 entities)5$178
Pfizer9$132
Regeneron1$125
Sight Sciences, Inc.1$121
Cequr Corporation3$121
Tolmar, Inc.6$94
Insulet Corporation4$91
Exelixis Inc.1$87
Currax Pharmaceuticals LLC5$87
Acella Pharmaceuticals, LLC1$67
Dexcom, Inc.3$56
Shire North American Group Inc4$55
Antares Pharma, Inc.3$45
Zealand Pharma US, Inc.3$42
Rhythm Pharmaceuticals, Inc.2$40
Bristol Myers Squibb1$40
BETA Bionics, Inc.2$31
Ipsen Biopharmaceuticals, Inc2$31
Johnson & Johnson2$30
EBI, LLC1$28
Astellas Pharma US Inc1$23
EUSA Pharma (US) LLC1$17
Recordati_rare_diseases_inc.1$17
Bigfoot Biomedical Inc1$15
Intra-sana Laboratories1$15
IBSA Pharma Inc.1$14
Neurocrine Biosciences, Inc.1$14
Eisai Inc.1$11

How this compares

$20,289 in reported general payments places this provider in the 85th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.

See all endocrinology, diabetes & metabolism providers in New Jersey →

Medicare billing

Part B allowed, 2024
$243,585
Medicare patients
343
Services billed
5,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Fort Lee

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →